Title of article
Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent
Author/Authors
Rha، نويسنده , , Seung-Woon and Kuchulakanti، نويسنده , , Pramod K. and Pakala، نويسنده , , Rajbabu and Cheneau، نويسنده , , Edouard and Fournadjiev، نويسنده , , Jana A. and Pinnow، نويسنده , , Ellen and GebreEyesus، نويسنده , , Afework and Aggrey، نويسنده , , George and Wang، نويسنده , , Zuyue and Pichard، نويسنده , , Augusto D. and Satler، نويسنده , , Lowell F. and Kent، نويسنده , , Kenneth M. ، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2004
Pages
4
From page
1047
To page
1050
Abstract
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
Journal title
American Journal of Cardiology
Serial Year
2004
Journal title
American Journal of Cardiology
Record number
1898251
Link To Document